by Fred Dumais | Nov 20, 2023 | News Release
Costs reduction initiatives and organizational realignment expected to generate annual savings exceeding $2 million. MONTREAL, QUEBEC, November 20, 2023 – Valeo Pharma Inc. (TSX: VPH, OTCQB: VPHIF, FSE: VP2) (“Valeo” or the “Company”), a Canadian pharmaceutical...
by Fred Dumais | Nov 7, 2023 | News Release
MONTREAL, QUEBEC, November 7, 2023 – Valeo Pharma Inc. (TSX: VPH, OTCQB: VPHIF, FSE: VP2) (“Valeo” or the “Company”), a Canadian pharmaceutical company, today announced that Mr. Richard Lajoie has joined the Company’s Board of Directors and that Ms. Maureen C....
by Fred Dumais | Oct 4, 2023 | News Release
MONTREAL, QUEBEC , October 4, 2023 – Valeo Pharma Inc. (TSX:VPH, OTCQB: VPHIF, FSE:VP2) (“Valeo” or the “Company”), a Canadian pharmaceutical company, is pleased to announce it placed No. 151 on the 2023 Report on Business ranking of Canada’s Top Growing...
by Fred Dumais | Sep 27, 2023 | News Release
MONTREAL, QUEBEC , September 27, 2023 – Valeo Pharma Inc. (TSX:VPH, OTCQB: VPHIF, FSE:VP2) (“Valeo” or the “Company”), a Canadian pharmaceutical company, announced today that it has entered into a credit facility agreement with Accord Financial Inc. The $5 million...
by Fred Dumais | Sep 13, 2023 | News Release
Seventh consecutive quarter of revenue growth at $14.1 million in Q3-23, up 132% over Q3-22. Physicians prescribing Enerzair and Atectura reached 2,503 at the end of Q3-23, representing a 23% increase from the prior quarter and a 221% rise year-over-year Total...
by Fred Dumais | Sep 7, 2023 | News Release
MONTREAL, QUEBEC , September 7, 2023 – Valeo Pharma Inc. (TSX:VPH, OTCQB: VPHIF, FSE:VP2) (“Valeo” or the “Company”), a Canadian pharmaceutical company, announced today that it will report its financial results and highlights for the third quarter ended July 31, 2023...
